Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Conference News ESC 2023

Avoid Using Prasugrel With Cangrelor During PCI, SWAP-6 Affirms

Todd Neale

August 22, 2023

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Michael O'Riordan

November 29, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Current NSAID Use Linked to Increased Risk of Heart Failure, Large European Analysis Shows

Michael O'Riordan

September 30, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

Italian Generic Clopidogrel Worse Than Brand Name at Suppressing Platelets

Jason Kahn

December 13, 2012

Advertisement

Bempedoic Acid Gains CV Risk Reduction Indication

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Avoid Using Prasugrel With Cangrelor During PCI, SWAP-6 Affirms

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

TCTMD’s Top 10 Most Popular Stories for August 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Current NSAID Use Linked to Increased Risk of Heart Failure, Large European Analysis Shows

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Italian Generic Clopidogrel Worse Than Brand Name at Suppressing Platelets

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content